FENC
Fennec Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.39
−1.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 59.2M | 44.6M | 47.5M | 21.3M | 1.5M |
| Cost of Revenue | 3.7M | 3.8M | 3.2M | 1.3M | 86.0K |
| Gross Profit | 55.5M | 40.9M | 44.4M | 20.0M | 1.4M |
| Operating Expenses | |||||
| R&D Expense | 216.0K | 250.0K | 307.0K | 56.0K | 3.5M |
| SG&A Expense | 56.4M | 46.9M | 41.5M | 32.7M | 20.5M |
| General & Admin Expense | 23.0M | 28.3M | 23.1M | 20.6M | 17.7M |
| Selling & Marketing Expense | 33.4M | 18.6M | 18.4M | 12.1M | 2.8M |
| Other Expenses | 38.0K | 64.0K | 89.0K | 287.0K | 149.0K |
| Total Operating Expenses | 56.7M | 47.2M | 41.9M | 33.1M | 24.2M |
| Cost and Expenses | 60.4M | 51.0M | 45.1M | 34.3M | 24.3M |
| Operating Income (EBIT) | (1.2M) | (6.3M) | 2.5M | (13.1M) | (22.7M) |
| Non-Operating | |||||
| Interest Income | 1.0M | 787.0K | 1.6M | 441.0K | 195.0K |
| Interest Expense | 904.0K | 2.1M | 4.1M | 3.4M | 978.0K |
| Net Interest Income | 102.0K | (1.3M) | (2.5M) | (3.0M) | (783.0K) |
| Other Non-Op Income/Expense | (1.9M) | (3.3M) | (2.5M) | (3.0M) | (976.0K) |
| Non-Operating Income (excl Interest) | 1.3M | 1.2M | (1.5M) | (407.0K) | (2.0K) |
| EBT (Pre-Tax Income) | (3.1M) | (9.6M) | (71.0K) | (16.0M) | (23.7M) |
| Income Tax Expense | 148.0K | 106.0K | 365.0K | — | — |
| Bottom Line | |||||
| Net Income | (3.3M) | (9.7M) | (436.0K) | (16.0M) | (23.7M) |
| Earnings from Cont. Ops | (3.3M) | (9.7M) | (436.0K) | (16.0M) | (23.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.3M) | (9.7M) | (436.0K) | (16.0M) | (23.7M) |
| Per Share | |||||
| Basic EPS | ($0.13) | ($0.36) | ($0.02) | ($0.60) | ($0.95) |
| Diluted EPS | ($0.14) | ($0.36) | ($0.02) | ($0.60) | ($0.95) |
| Revenue Per Share | $1.71 | $1.56 | $1.74 | $0.80 | $0.06 |
| Shares | |||||
| Basic Shares Outstanding | 34.5M | 28.6M | 27.3M | 26.6M | 26.3M |
| Diluted Shares Outstanding | 36.4M | 28.6M | 27.3M | 26.6M | 26.3M |
| Profitability Metrics | |||||
| EBITDA | (2.4M) | (7.5M) | 4.8M | (12.4M) | (22.6M) |
| D&A | 104.0K | 103.0K | 800.0K | 287.0K | 149.0K |
| EBIT | (2.5M) | (7.6M) | 4.0M | (12.7M) | (22.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026